Kaifeng Lu

4.7k total citations · 2 hit papers
87 papers, 3.3k citations indexed

About

Kaifeng Lu is a scholar working on Psychiatry and Mental health, Statistics and Probability and Management Science and Operations Research. According to data from OpenAlex, Kaifeng Lu has authored 87 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Psychiatry and Mental health, 34 papers in Statistics and Probability and 10 papers in Management Science and Operations Research. Recurrent topics in Kaifeng Lu's work include Statistical Methods in Clinical Trials (25 papers), Statistical Methods and Bayesian Inference (25 papers) and Schizophrenia research and treatment (21 papers). Kaifeng Lu is often cited by papers focused on Statistical Methods in Clinical Trials (25 papers), Statistical Methods and Bayesian Inference (25 papers) and Schizophrenia research and treatment (21 papers). Kaifeng Lu collaborates with scholars based in United States, Hungary and India. Kaifeng Lu's co-authors include Suresh Durgam, I. Laszlovszky, Joel M. Trugman, Jessica Ailani, David W. Dodick, Armin Szegedi, Richard B. Lipton, Michelle Finnegan, Ronald Brazg and Julio Rosenstock and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Kaifeng Lu

84 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ubrogepant for the Treatment of Migraine

2019 253 citations David W. Dodick, Richard B. Lipton et al. profile →
Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial

2023 75 citations Peter J. Goadsby, Richard B. Lipton et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kaifeng Lu United States	29	1.9k	628	492	482	384	87	3.3k
Yili Pritchett United States	34	805 0.4×	395 0.6×	1.3k 2.7×	348 0.7×	1.3k 3.3×	57	4.4k
Anna‐Maija Tolppanen Finland	34	1.3k 0.7×	346 0.6×	845 1.7×	229 0.5×	208 0.5×	172	3.7k
Shelia Jin United States	16	1.3k 0.7×	231 0.4×	1.5k 3.0×	480 1.0×	907 2.4×	28	3.9k
Elyse Stock United States	15	2.5k 1.3×	471 0.8×	467 0.9×	197 0.4×	334 0.9×	44	3.0k
Olivier Rouaud France	33	1.2k 0.6×	158 0.3×	794 1.6×	367 0.8×	253 0.7×	119	4.2k
Joel Raskin United States	35	1.6k 0.8×	191 0.3×	1.7k 3.4×	174 0.4×	1.9k 4.8×	86	4.5k
Yili Lu United States	19	1.2k 0.7×	97 0.2×	832 1.7×	203 0.4×	1.7k 4.5×	32	3.4k
Marc Kamin United States	31	1.8k 1.0×	184 0.3×	1.0k 2.0×	113 0.2×	1.1k 3.0×	61	4.0k
Beverly N. Jones United States	18	2.4k 1.3×	445 0.7×	993 2.0×	1.2k 2.5×	262 0.7×	23	5.0k
Hong Liu‐Seifert United States	25	1.5k 0.8×	112 0.2×	1.7k 3.4×	107 0.2×	1.0k 2.7×	53	3.6k

Countries citing papers authored by Kaifeng Lu

Since Specialization

Citations

This map shows the geographic impact of Kaifeng Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kaifeng Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kaifeng Lu more than expected).

Fields of papers citing papers by Kaifeng Lu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kaifeng Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kaifeng Lu. The network helps show where Kaifeng Lu may publish in the future.

Co-authorship network of co-authors of Kaifeng Lu

This figure shows the co-authorship network connecting the top 25 collaborators of Kaifeng Lu. A scholar is included among the top collaborators of Kaifeng Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kaifeng Lu. Kaifeng Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

He, Shan, Kaifeng Lu, Xuan Wang, et al.. (2025). Effect of sheep placenta extract on D-galactose-induced aging mouse. Frontiers in Pharmacology. 16. 1498358–1498358.

Dodick, David W., Peter J. Goadsby, Todd J. Schwedt, et al.. (2023). Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA. The Lancet. 402(10419). 2307–2316. 48 indexed citations

Li, Xiaoyun, et al.. (2023). A variation of a 2-in-1 adaptive design to seamlessly expand a selected dose from a phase 2 trial to a phase 3 trial for oncology drug development. Contemporary Clinical Trials. 127. 107119–107119. 2 indexed citations

Fava, Maurizio, Suresh Durgam, Willie Earley, et al.. (2018). Efficacy of adjunctive low-dose cariprazine in major depressive disorder. International Clinical Psychopharmacology. 33(6). 312–321. 43 indexed citations

Ketter, Terence A., Roy H. Perlis, Suresh Durgam, et al.. (2017). The safety and tolerability of cariprazine in patients with manic or mixed episodes associated with bipolar I disorder: A 16-week open-label study. Journal of Affective Disorders. 225. 350–356. 29 indexed citations

Earley, Willie, Suresh Durgam, Kaifeng Lu, et al.. (2017). Tolerability of cariprazine in the treatment of acute bipolar I mania: A pooled post hoc analysis of 3 phase II/III studies. Journal of Affective Disorders. 215. 205–212. 25 indexed citations

Earley, Willie, Suresh Durgam, Kaifeng Lu, et al.. (2017). Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia. International Clinical Psychopharmacology. 32(6). 319–328. 50 indexed citations

Cutler, Andrew J., Suresh Durgam, Yao Wang, et al.. (2017). Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study. CNS Spectrums. 23(1). 39–50. 47 indexed citations

Earley, Willie, Suresh Durgam, Kaifeng Lu, et al.. (2017). Clinically relevant response and remission outcomes in cariprazine-treated patients with bipolar I disorder. Journal of Affective Disorders. 226. 239–244. 29 indexed citations

10.

Citrome, Leslie, Suresh Durgam, Kaifeng Lu, Paul Ferguson, & I. Laszlovszky. (2016). The Effect of Cariprazine on Hostility Associated With Schizophrenia. The Journal of Clinical Psychiatry. 77(1). 109–115. 31 indexed citations

11.

Durgam, Suresh, Andrew J. Cutler, Kaifeng Lu, et al.. (2015). Cariprazine in Acute Exacerbation of Schizophrenia. The Journal of Clinical Psychiatry. 76(12). e1574–e1582. 137 indexed citations

12.

Kane, John M., Stephen R. Zukin, Yao Wang, et al.. (2015). Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia. Journal of Clinical Psychopharmacology. 35(4). 367–373. 148 indexed citations

13.

Perlis, Roy H., William M. Greenberg, Anju Starace, et al.. (2014). Cariprazine in the treatment of acute mania in bipolar I disorder: A double-blind, placebo-controlled, Phase III trial. Journal of Affective Disorders. 174. 296–302. 90 indexed citations

14.

Lu, Kaifeng. (2013). An analytic method for the placebo‐based pattern‐mixture model. Statistics in Medicine. 33(7). 1134–1145. 28 indexed citations

15.

Kipnes, Mark, Priscilla Hollander, Ken Fujioka, et al.. (2009). A one‐year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes. Diabetes Obesity and Metabolism. 12(6). 517–531. 43 indexed citations

16.

Lu, Kaifeng, et al.. (2008). Sample Size Estimation for Repeated Measures Analysis in Randomized Clinical Trials with Missing Data. The International Journal of Biostatistics. 4(1). Article 9–Article 9. 54 indexed citations

17.

Erondu, Ngozi, Carol Addy, Kaifeng Lu, et al.. (2007). NPY5R Antagonism Does Not Augment the Weight Loss Efficacy of Orlistat or Sibutramine. Obesity. 15(8). 2027–2042. 23 indexed citations

18.

Yang, Jie, et al.. (2007). Adaptive Design for Censored Survival Data Adjusting for Covariates. Sequential Analysis. 26(1). 89–97.

19.

Lu, Kaifeng & Anastasios A. Tsiatis. (2005). Comparison Between Two Partial Likelihood Approaches for the Competing Risks Model with Missing Cause of Failure. Lifetime Data Analysis. 11(1). 29–40. 19 indexed citations

20.

Lu, Kaifeng & Anastasios A. Tsiatis. (2001). Multiple Imputation Methods for Estimating Regression Coefficients in the Competing Risks Model with Missing Cause of Failure. Biometrics. 57(4). 1191–1197. 95 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact